Skip to main content

Advertisement

Table 3 Use of specific second-line anti-TB or antiretroviral medicines and the risk of moderate-to-severe adverse events

From: Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study

Anti-TB medicine Number (%) treated with the medicine, N = 57 Univariate risk ratios 95% confidence interval p-value
Amikacin 21 (36.8%) 1.5 0.8 – 2.6 0.18
Amoxicillin/Clavulanate 1 (1.8%) 0.0 - 0.36
Capreomycin 4 (7%) 1.1 0.4 – 3.1 0.86
Ciprofloxacin 19 (33.3%) 1.5 0.8 – 2.5 0.19
Clofazimine 1 (1.8%) 0 - 0.36
Cycloserine 27 (47.4%) 0.8 0.5 – 1.5 0.49
Ethambutol 35 (61.4%) 1.7 0.9 – 3.4 0.10
Ethionamide 52 (91.2%) 0.7 0.3 – 1.6 0.50
Isoniazid 4 (7%) 1.1 0.4 – 3.1 0.86
Kanamycin 30 (52.6%) 0.8 0.4 – 1.4 0.37
Levofloxacin 37 (64.9%) 0.6 0.4 – 1.1 0.11
Para aminosalicylic acid (PAS) 5 (8.8%) 1.4 0.6 – 2.9 0.50
Pyrazinamide 53 (93%) 0.9 0.3 – 2.5 0.86
Rifampicin 13 (22.8%) 0.8 0.4 – 1.7 0.56
Streptomycin 3 (5.3%) 0.7 0.1 – 3.6 0.66
Any HAART regimen 13 (22.8%) 0.8 0.4 – 1.7 0.56
Zidovudine (AZT) 5 (8.8%) 0.4 0.1 – 2.5 0.23
Stavudine (d4T) 6 (10.5%) 1.1 0.5 – 2.6 0.82
Efavirenz (EFV) 10 (17.5%) 0.9 0.4 – 1.9 0.70
Nevirapine (NVP) 3 (5.3%) 0.7 0.1 – 3.7 0.66